Jesse McGreivy
About
Jesse McGreivy is a scholar working on Oncology, Genetics and Hematology.
According to data from OpenAlex, Jesse McGreivy has authored 41 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Genetics and 13 papers in Hematology. Recurrent topics in Jesse McGreivy's work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Jesse McGreivy is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Jesse McGreivy collaborates with scholars based in United States, France and Australia. Jesse McGreivy's co-authors include Elwyn Loh, J.F.R. Robertson, Hugues Bourgeois, Hagen F. Kennecke, William Jacot, Samuel Suzuki, Ian McCaffery, Jean-Marc Ferrero, Richard H. De Boer and Peter A. Kaufman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Jesse McGreivy
40 papers receiving 691 citations
Peers
Jesse McGreivy
Carrie Brownstein United States
Kerry D. Lynch United States
Neelima G. Reddy United States
Stephen Castaneda United States
Lydia Sánchez-Verde Spain
Juergen Mestan Switzerland
Siobhan Ng Australia
Raquel Longarón Spain
Dominique Vaur France
Konrad Aumann Germany
Citations per year, relative to Jesse McGreivy Jesse McGreivy (= 1×)
peers
Carrie Brownstein
Countries citing papers authored by Jesse McGreivy
Since
Specialization
Citations
This map shows the geographic impact of Jesse McGreivy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse McGreivy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse McGreivy more than expected).
Fields of papers citing papers by Jesse McGreivy
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jesse McGreivy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse McGreivy. The network helps show where Jesse McGreivy may publish in the future.
Co-authorship network of co-authors of Jesse McGreivy
This figure shows the co-authorship network connecting the top 25 collaborators of Jesse McGreivy. A scholar is included among the top collaborators of Jesse McGreivy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse McGreivy. Jesse McGreivy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483.
2.
Popov, Viola Maria, Sanjay Mohan, Zübeyde Nur Özkurt, et al.. (2024). Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 1000–1000.
3.
Loschi, Michaël, László Rejtő, Marianna Caramella, et al.. (2023). P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL). HemaSphere. 7(S3). e09624cd–e09624cd.
4.
Byrd, John C., Dariusz Woszczyk, Árpád Illés, et al.. (2023). A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood. 142(Supplement 1). 4634–4634.
5.
Verstovšek, Srđan, Haifa Kathrin Al‐Ali, John Mascarenhas, et al.. (2022). BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis. Future Oncology. 18(37). 4059–4069.
6.
Dowlati, Afshin, Sandrine Hiret, Achim Rittmeyer, et al.. (2022). An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS8600–TPS8600.
7.
Lange, Andrzej, Haifa Kathrin Al‐Ali, Jesús María Hernández‐Rivas, et al.. (2021). Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF). Blood. 138(Supplement 1). 3581–3581.
8.
Verstovšek, Srđan, Haifa Kathrin Al‐Ali, John Mascarenhas, et al.. (2021). BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).. Journal of Clinical Oncology. 39(15_suppl). TPS7057–TPS7057.
9.
Bellmunt, Joaquim, Sumanta K. Pal, Joel Picus, et al.. (2017). Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 4540–4540.
10.
Furtado, Michelle, Michael Wang, Brian Munneke, et al.. (2015). Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. British Journal of Haematology. 170(1). 131–134.
11.
Sukbuntherng, Juthamas, David Loury, Jan de Jong, et al.. (2014). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemotherapy and Pharmacology. 75(1). 111–121.
12.
Byrd, John C., Jennifer R. Brown, Susan O’Brien, et al.. (2014). Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. Journal of Clinical Oncology. 32(18_suppl). LBA7008–LBA7008.
13.
Robertson, J.F.R., Jean-Marc Ferrero, Hugues Bourgeois, et al.. (2013). Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. The Lancet Oncology. 14(3). 228–235.
14.
Kindler, Hedy L., Donald Richards, Lawrence Garbo, et al.. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology. 23(11). 2834–2842.
15.
Lorigan, Paul, J.C. Soria, Joan Stephenson, et al.. (2010). Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc). Annals of Oncology. 21. 149–149.
16.
Ferrero, J-M, Hugues Bourgeois, Hagen F. Kennecke, et al.. (2010). Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC). Cancer Research. 70(24_Supplement). S1–4.
17.
Price, Timothy, et al.. (2008). Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer. 99(9). 1387–1394.
18.
LoRusso, Patricia, Elisabeth I. Heath, Jesse McGreivy, et al.. (2008). Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Investigational New Drugs. 26(5). 455–462.
19.
Blumenschein, George R., Alan Sandler, Timothy J. O’Rourke, et al.. (2007). PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S469–S469.
20.
Schwartzberg, Lee S., Herbert I. Hurwitz, Dusan Kotasek, et al.. (2007). Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 25(18_suppl). 4081–4081.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carrie Brownstein Breakdown of academic impact, for papers by Kerry D. Lynch Breakdown of academic impact, for papers by Neelima G. Reddy Breakdown of academic impact, for papers by Stephen Castaneda Breakdown of academic impact, for papers by Lydia Sánchez-Verde Breakdown of academic impact, for papers by Juergen Mestan Breakdown of academic impact, for papers by Siobhan Ng Breakdown of academic impact, for papers by Raquel Longarón Breakdown of academic impact, for papers by Dominique Vaur Breakdown of academic impact, for papers by Konrad Aumann